Hypertension and diabetes

Advances in Cardiology

Volumn 45, Issue , 2008, Pages 82-106

  Grossman, E ^a   Messerli, F ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ATHEROSCLEROSIS; CARDIOMYOPATHY; CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; HEALTH; HUMAN; HYPERTENSION; MIDDLE AGED; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; UNITED STATES;

ADULT; AGED; ATHEROSCLEROSIS; CARDIOMYOPATHIES; CORONARY DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PREVALENCE; UNITED STATES; WORLD HEALTH;

EID: 43749094137     PISSN: 00652326     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000115189     Document Type: Review

References (134)

1. Grossman E, Messerli FH: Diabetic and hypertensive heart disease. Ann Intern Med 1996;125:304-310.
2. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000;342:905-912.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444.
4. Haffner SJ, Cassells H: Hyperglycemia as a cardiovascular risk factor. Am J Med 2003;115(suppl 8A):6S-11S.
5. Brown MJ, Castaigne A, de Leeuw PW, et al: Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension 2000;35:1038-1042.
6. Messerli FH, Grossman E, Leonetti G: Antihypertensive therapy and new onset diabetes. J Hypertens 2004;22:1845-1847.
7. Harris MI, Flegal KM, Cowie CC, et al: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-524.
8. Drivsholm T, Ibsen H, Schroll M, Davidsen M, Borch-Johnsen K: Increasing prevalence of diabetes mellitus and impaired glucose tolerance among 60-year-old Danes. Diabet Med 2001;18:126-132.
9. Pan XR, Yang WY, Li GW, Liu J: Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative Group. Diabetes Care 1997;20:1664-1669.
10. Ramachandran A, Snehalatha C, Latha E, Vijay V, Viswanathan M: Rising prevalence of NIDDM in an urban population in India. Diabetologia 1997;40:232-237.
11. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-1431.
12. Zimmet P, Alberti KG, Shaw J: Global and societal implications of the diabetes epidemic. Nature 2001;414:782-787.
13. Harris SB, Gittelsohn J, Hanley A, et al: The prevalence of NIDDM and associated risk factors in native Canadians. Diabetes Care 1997;20:185-187.
14. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197.
15. Dunstan DW, Zimmet PZ, Welborn TA, et al: The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002;25:829-834.
16. Isomaa B, Almgren P, Tuomi T, et al: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-689.
17. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J: Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-223.
18. Sowers JR: Recommendations for special populations: diabetes mellitus and the metabolic syndrome. Am J Hypertens 2003;16:41S-45S.
19. Arauz-Pacheco C, Parrott MA, Raskin P: The treatment of hypertension in adult patients with diabetes. Diabetes Care 2002;25:134-147.
20. Rosendorff C, Black HR, Cannon CP, et al: Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007;115:2761-2788.
21. Grossman E, Messerli FH, Goldbourt U: High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal? Arch Intern Med 2000;160:2447-2452.
22. Shaw JE, Zimmet PZ, Hodge AM, et al: Impaired fasting glucose: how low should it go? Diabetes Care 2000;231:34-39.
23. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K: Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004;164:1066-1076.
24. Mancia G, De Backer G, Dominiczak A, et al: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-1187.
25. Schillaci G, Pirro M, Vaudo G, et al: Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004;43:1817-1822.
26. Sowers JR, Epstein M, Frohlich ED: Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001;37:1053-1059.
27. Carrozza JP Jr, Kuntz RE, Fishman RF, Baim DS: Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 1993;118:344-349.
28. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 1996;335:217-225.
29. Nesto RW, Phillips RT, Kett KG, et al: Angina and exertional myocardial ischemia in diabetic and nondiabetic patients: assessment by exercise thallium scintigraphy. Ann Intern Med 1988;108:170-175.
30. Haffner SM, Lehto S, Ronnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234.
31. Hoffman JI: A critical view of coronary reserve. Circulation 1987;75:I6-I11.
32. Grossman E, Rosenthal T: Hypertensive heart disease and the diabetic patient. Curr Opin Cardiol 1995;10:458-465.
33. Kannel WB, Dannenberg AL, Abbott RD: Unrecognized myocardial infarction and hypertension: the Framingham Study. Am Heart J 1985;109:581-585.
34. Assmann G, Schulte H: The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988;116:1713-1724.
35. Melina D, Colivicchi F, Melina G, Pristipino C: Prevalence of silent ST segment depression during long-term ambulatory electrocardiographic monitoring in asymptomatic diabetic patients with essential hypertension. Minerva Med 1993;84:301-305.
36. Kannel WB, Hjortland M, Castelli WP: Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974;34:29-34.
37. Schannwell CM, Schneppenheim M, Perings S, Plehn G, Strauer BE: Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology 2002;98:33-39.
38. Shapiro LM: Echocardiographic features of impaired ventricular function in diabetes mellitus. Br Heart J 1982;47:439-444.
39. Borow KM, Jaspan JB, Williams KA, Neumann A, Wolinski-Walley P, Lang RM: Myocardial mechanics in young adult patients with diabetes mellitus: effects of altered load, inotropic state and dynamic exercise. J Am Coll Cardiol 1990;15:1508-1517.
40. Mustonen JN, Uusitupa MI, Laakso M, et al: Left ventricular systolic function in middle-aged patients with diabetes mellitus. Am J Cardiol 1994;73:1202-1208.
41. Iwasaka T, Sugiura T, Abe Y, et al: Residual left ventricular pump function following acute myocardial infarction in postmenopausal diabetic women. Coron Artery Dis 1994;5:237-242.
42. Gustafsson I, Hildebrandt P: Early failure of the diabetic heart. Diabetes Care 2001;24:3-4.
43. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.
44. Shindler DM, Kostis JB, Yusuf S, et al: Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am J Cardiol 1996;77:1017-1020.
45. Blendea MC, McFarlane SI, Isenovic ER, Gick G, Sowers JR: Heart disease in diabetic patients. Curr Diab Rep 2003;3:223-229.
46. Malmberg K, Ryden L, Efendic S, et al: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26:57-65.
47. Henry P, Thomas F, Benetos A, Guize L: Impaired fasting glucose, blood pressure and cardiovascular disease mortality. Hypertension 2002;40:458-463.
48. Marroquin OC, Kip KE, Kelley DE, et al: Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women's Ischemia Syndrome Evaluation. Circulation 2004;109:714-721.
49. Drayer JI, Gardin JM, Brewer DD, Weber MA: Disparate relationships between blood pressure and left ventricular mass in patients with and without left ventricular hypertrophy. Hypertension 1987;9:II61-II64.
50. Frohlich ED, Apstein C, Chobanian AV, et al: The heart in hypertension. N Engl J Med 1992;327:998-1008.
51. Mercadier JJ, Lompre AM, Wisnewsky C, et al: Myosin isoenzyme changes in several models of rat cardiac hypertrophy. Circ Res 1981;49:525-532.
52. Grossman E, Oren S, Messerli FH: Left ventricular mass and cardiac function in patients with essential hypertension. J Hum Hypertens 1994;8:417-421.
53. Devereux RB: Left ventricular diastolic dysfunction: early diastolic relaxation and late diastolic compliance. J Am Coll Cardiol 1989;13:337-339.
54. Gerdts E, Bjornstad H, Toft S, Devereux RB, Omvik P: Impact of diastolic Doppler indices on exercise capacity in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy). J Hypertens 2002;20:1223-1229.
55. Grossman E, Oren S, Messerli FH: Left ventricular filling and stress response pattern in essential hypertension. Am J Med 1991;91:502-506.
56. Skaluba SJ, Litwin SE: Mechanisms of exercise intolerance: insights from tissue Doppler imaging. Circulation 2004;109:972-977.
57. Kannel WB, Castelli WP, McNamara PM, McKee PA, Feinleib M: Role of blood pressure in the development of congestive heart failure. The Framingham study. N Engl J Med 1972;287:781-787.
58. Garty M, Shotan A, Gottlieb S, et al: The management, early and one year outcome in hospitalized patients with heart failure: a national Heart Failure Survey in Israel-HFSIS 2003. Isr Med Assoc J 2007;9:227-233.
59. Lewis BS, Shotan A, Gottlieb S, et al: Late mortality and determinants in patients with heart failure and preserved systolic left ventricular function: the Israel Nationwide Heart Failure Survey. Isr Med Assoc J 2007;9:234-238.
60. Haider AW, Larson MG, Franklin SS, Levy D: Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 2003;138:10-16.
61. Kannel WB: Prevalence and natural history of electrocardiographic left ventricular hypertrophy. Am J Med 1983;75:4-11.
62. van Hoeven KH, Factor SM: A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 1990;82:848-855.
63. Grossman E, Shemesh J, Shamiss A, Thaler M, Carroll J, Rosenthal T: Left ventricular mass in diabetes-hypertension. Arch Intern Med 1992;152:1001-1004.
64. Venco A, Grandi A, Barzizza F, Finardi G: Echocardiographic features of hypertensive-diabetic heart muscle disease. Cardiology 1987;74:28-34.
65. Sahai A, Ganguly PK: Congestive heart failure in diabetes with hypertension may be due to uncoupling of the atrial natriuretic peptide receptor-effector system in the kidney basolateral membrane. Am Heart J 1991;122:164-170.
66. Lea JP, Nicholas SB: Diabetes mellitus and hypertension: key risk factors for kidney disease. J Natl Med Assoc 2002;94(8 suppl):7S-15S.
67. Chaiken RL, Eckert-Norton M, Bard M, et al: Hyperfiltration in African-American patients with type 2 diabetes: cross-sectional and longitudinal data. Diabetes Care 1998;21:2129-2134.
68. Burnier M, Zanchi A: Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 2006;24:11-25.
69. Gerstein HC, Mann JF, Yi Q, et al: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-426.
70. National High Blood Pressure Education Program Working Group report on hypertension and chronic renal failure. Arch Intern Med 1991;151:1280-1287.
71. Klag MJ, Whelton PK, Randall BL, et al: Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334:13-18.
72. Bakris GL, Williams M, Dworkin L, et al: Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36:646-661.
73. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287:2570-2581.
74. Newman AB, Siscovick DS, Manolio TA, et al: Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation 1993;88:837-845.
75. Abbott RD, Brand FN, Kannel WB: Epidemiology of some peripheral arterial findings in diabetic men and women: experiences from the Framingham Study. Am J Med 1990;88:376-381.
76. Hiatt WR, Hirsch AT, Regensteiner JG, Brass EP: Clinical trials for claudication: assessment of exercise performance, functional status, and clinical end points. Vascular clinical trialists. Circulation 1995;92:614-621.
77. Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE: Peripheral arterial disease in the elderly: The Rotterdam Study. Arterioscler Thromb Vasc Biol 1998;18:185-192.
78. Kallio M, Forsblom C, Groop PH, Groop L, Lepantalo M: Development of new peripheral arterial occlusive disease in patients with type 2 diabetes during a mean follow-up of 11 years. Diabetes Care 2003;26:1241-1245.
79. Jude EB, Oyibo SO, Chalmers N, Boulton AJ: Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care 2001;24:1433-1437.
80. Beks PJ, Mackaay AJ, de Neeling JN, de Vries H, Bouter LM, Heine RJ: Peripheral arterial disease in relation to glycaemic level in an elderly Caucasian population: the Hoorn study. Diabetologia 1995;38:86-96.
81. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K: 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation 1990;82:27-36.
82. Hooi JD, Kester AD, Stoffers HE, Overdijk MM, van Ree JW, Knottnerus JA: Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study. Am J Epidemiol 2001;153:666-672.
83. Dormandy JA, Rutherford RB: Management of peripheral arterial disease (PAD). TASC Working Group: TransAtlantic Inter-Society Concensus (TASC). J Vasc Surg 2000;31:S1-S296.
84. Friedlander AH, Maeder LA: The prevalence of calcified carotid artery atheromas on the panoramic radiographs of patients with type 2 diabetes mellitus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;89:420-424.
85. Himmelmann A, Hansson L, Svensson A, Harmsen P, Holmgren C, Svanborg A: Predictors of stroke in the elderly. Acta Med Scand 1988;224:439-443.
86. Tanne D, Goldbourt U, Koton S, et al: A national survey of acute cerebrovascular disease in Israel: burden, management, outcome and adherence to guidelines. Isr Med Assoc J 2006;8:3-7.
87. Folsom AR, Rasmussen ML, Chambless LE, et al: Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Diabetes Care 1999;22:1077-1083.
88. Jamrozik K, Broadhurst RJ, Forbes S, Hankey GJ, Anderson CS: Predictors of death and vascular events in the elderly: the Perth Community Stroke Study. Stroke 2000;31:863-868.
89. Jorgensen H, Nakayama H, Raaschou HO, Olsen TS: Stroke in patients with diabetes. The Copenhagen Stroke Study. Stroke 1994;25:1977-1984.
90. You RX, McNeil JJ, O'Malley HM, Davis SM, Thrift AG, Donnan GA: Risk factors for stroke due to cerebral infarction in young adults. Stroke 1997;28:1913-1918.
91. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R: Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001;154:635-641.
92. Hankey GJ, Jamrozik K, Broadhurst RJ, et al: Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke 1998;29:2491-2500.
93. Tuomilehto J, Rastenyte D, Jousilahti P, Sarti C, Vartiainen E: Diabetes mellitus as a risk factor for death from stroke: prospective study of the middle-aged Finnish population. Stroke 1996;27:210-215.
94. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-1913.
95. Staessen JA, Gasowski J, Wang JG, et al: Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000;355:865-872.
96. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713.
97. Knowler WC, Bennett PH, Ballintine EJ: Increased incidence of retinopathy in diabetics with elevated blood pressure: a six-year follow-up study in Pima Indians. N Engl J Med 1980;302:645-650.
98. Messerli FH, Mancia G, Conti CR, et al: Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006;144:884-893.
99. Sjostrom L, Lindroos AK, Peltonen M, et al: Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683-2693.
100. Julius S, Kjeldsen SE, Weber M, et al: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031.
101. Standards of medical care in diabetes. Diabetes Care 2004;27(suppl 1):S15-S35.
102. Rossing K, Jacobsen P, Pietraszek L, Parving HH: Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 2003;26:2268-2274.
103. Granger CB, McMurray JJ, Yusuf S, et al: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-776.
104. Calhoun DA: Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J Clin Hypertens (Greenwich) 2007;9(suppl 1):19-24.
105. Chapman N, Dobson J, Wilson S, et al: Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49:839-845.
106. Croom KF, Perry CM: Eplerenone: a review of its use in essential hypertension. Am J Cardiovasc Drugs 2005;5:51-69.
107. Epstein M: Adding spironolactone to conventional antihypertensives reduces albuminuria in patients with diabetic nephropathy. Nat Clin Pract Nephrol 2006;2:310-311.
108. Goodfriend TL: Treating resistant hypertension with a neglected old drug. Hypertension 2007;49:763-764.
109. Sharabi Y, Adler E, Shamis A, Nussinovitch N, Markovitz A, Grossman E: Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens 2006;19:750-755.
110. Grossman E, Messerli FH: Are calcium antagonists beneficial in diabetic patients with hypertension? Am J Med 2004;116:44-49.
111. Boero R, Rollino C, Massara C, et al: The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study. Am J Kidney Dis 2003;42:67-75.
112. Messerli FH, Grossman E, Goldbourt U: Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998;279:1903-1907.
113. Dahlof B, Sever PS, Poulter NR, et al: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
114. Sever P: New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. J Renin Angiotensin Aldosterone Syst 2006;7:61-63.
115. Khan N, McAlister FA: Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006;174:1737-1742.
116. Giugliano D, Acampora R, Marfella R, et al: Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized, controlled trial. Ann Intern Med 1997;126:955-959.
117. Bakris GL, Fonseca V, Katholi RE, et al: Metabolic effects of carvedilol vs. metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004;292:2227-2236.
118. Shamiss A, Carroll J, Peleg E, Grossman E, Rosenthal T: The effect of enalapril with and without hydrochlorothiazide on insulin sensitivity and other metabolic abnormalities of hypertensive patients with NIDDM. Am J Hypertens 1995;8:276-281.
119. Cooper-Dehoff R, Cohen JD, Bakris GL, et al: Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol 2006;98:890-894.
120. Messerli FH, Grossman E, Lever AF: Do thiazide diuretics confer specific protection against strokes? Arch Intern Med 2003;163:2557-2560.
121. Puig JG, Marre M, Kokot F, et al: Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. Am J Hypertens 2007;20:90-97.
122. Barzilay JI, Davis BR, Cutler JA, et al: Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006;166:2191-2201.
123. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR: Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005;95:29-35.
124. Messerli FH: Implications of discontinuation of doxazosin arm of ALLHAT: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Lancet 2000;355:863-864.
125. Sowers JR, Haffner S: Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. Hypertension 2002;40:781-788.
126. Colhoun HM, Betteridge DJ, Durrington PN, et al: Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2005;48:2482-2485.
127. Snow V, Aronson MD, Hornbake ER, Mottur-Pilson C, Weiss KB: Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2004;140:644-649.
128. Lewis PJ, Kohner EM, Petrie A, Dollery CT: Deterioration of glucose tolerance in hypertensive patients on prolonged diuretic treatment. Lancet 1976;i:564-566.
129. Murphy MB, Lewis PJ, Kohner E, Schumer B, Dollery CT: Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up. Lancet 1982;2:1293-1295.
130. Mancia G, Grassi G, Zanchetti A: New-onset diabetes and antihypertensive drugs. J Hypertens 2006;24:3-10.
131. Yusuf S, Gerstein H, Hoogwerf B, et al: Ramipril and the development of diabetes. JAMA 2001;286:1882-1885.
132. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O: Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003;21:1563-1574.
133. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
134. Verdecchia P, Reboldi G, Angeli F, et al: Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004;43:963-969.